Reports describing the utility of EEG as a biomarker for MCI and/or AD have seen many advances during just the last 6 years, and hence this review will be limited to a consideration of literature published within the previous 6-year period. In addition, this review is further limited to studies applying qEEG while patients are awake and performing cognitive tasks. Although qEEG is routinely applied to collect electrophysiologic data during the resting state (eyes open or closed) and during sleep, this review will not focus on these behavioral states [40].